New drug duo aims to boost immune attack on tough head and neck cancers
NCT ID NCT07216833
Summary
This early-stage study is testing whether adding an experimental drug called decitabine can make an approved immunotherapy (nivolumab) work better against recurrent or spreading head and neck cancer. The main goals are to find the safest dose of the combination and see how it affects the body's immune response. It is for up to 15 adults whose cancer has returned or spread and who are eligible for first-line immunotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute
Cleveland, Ohio, 44195, United States
Contact
Contact
Conditions
Explore the condition pages connected to this study.